30 December 2014 : Original article
Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung CancerKeqian ZhangABD, Hong QinBCDEF, Feng PanBC, Enqiang LiuBC, Houjie LiangAD, Zhihua RuanAD
Med Sci Monit 2014; 20:2830-2836
BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC.
MATERIAL AND METHODS: We retrospectively reviewed patients with stage III-IV unresectable NSCLC from 1 January 2010 to 31 December 2013 at Southwest Hospital. They all received nedaplatin (80 mg/m2, nedaplatin group) or oxaliplatin (130 mg/m2, oxaliplatin group) combined with paclitaxel (175 mg/m2) or docetaxel (75 mg/m2) as first-line treatment.
RESULTS: There are 174 patients enrolled – 123 patients in the nedaplatin group and 51 patients in the oxaliplatin group. The objective response rates were 47.3% and 34.1% and the disease control rates were 87.5% and 79.5% in nedaplatin and oxaliplatin groups, respectively. The progression-free survival time was 10.4 months and 9.6 months (p=0.722) and the overall survival time was 18.5 months and 25.5 months in the nedaplatin and oxaliplatin groups, respectively (p=0.09). Total toxicity was greater in the oxaliplatin group (p=0.008), but there is no significant difference among ¾ grade adverse events between the 2 groups (P=0.595).
CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC.
Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Carcinoma, Non-Small-Cell Lung - pathology, Disease-Free Survival, Lung Neoplasms - pathology, Neoplasm Staging, Organoplatinum Compounds - therapeutic use, Paclitaxel - therapeutic use, Taxoids - therapeutic use
01 January 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
Med Sci Monit 2022; 28:e935952
11 January 2022 : Clinical ResearchA Remote Questionnaire-Based Study to Compare Alcohol Use in 1030 Final-Year High School Students in Split-...
Med Sci Monit In Press; DOI: 10.12659/MSM.935567
08 November 2021 : Database AnalysisVirtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Cor...
Med Sci Monit In Press; DOI: 10.12659/MSM.934102
31 December 2021 : Clinical ResearchA Prospective Observational Study of 42 Patients with COVID-19 infection and a History of Hepatitis C Virus...
Med Sci Monit 2021; 27:e935075
17 Jan 2022 : Clinical ResearchUnveiling the Differences in Biological Properties of Dental Pulp Stem Cells from Normal and Inflamed Pulp:...
Med Sci Monit In Press; DOI: 10.12659/MSM.934511
14 Jan 2022 : Database AnalysisIdentification of Key Genes Associated with Brain Metastasis from Breast Cancer: A Bioinformatics Analysis
Med Sci Monit In Press; DOI: 10.12659/MSM.935071
13 Jan 2022 : Review articleA Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hyperc...
Med Sci Monit In Press; DOI: 10.12659/MSM.935821
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996
05 Mar 2020 : Clinical ResearchThe Effects of Social Support on Sleep Quality of Medical Staff Treating Patients with Coronavirus Disease ...
Med Sci Monit 2020; 26:e923549